Trovagene Inc (TROV) 4.87 $TROV
Blue Cross Blue Shield Illinois to Cover Trovera(TM) Liquid Biopsy Tests
PR Newswire - Wed Aug 17, 7:30AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois (BCBSIL) establishing health benefit access to the full line of Trovagene's tests and services.
TROV: 4.87 (-0.04)
Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference
PR Newswire - Tue Aug 09, 9:34AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 2016 Avondale Partners Healthcare 1-1 Conference on Wednesday, August 10, 2016 at the Boston Harbor Hotel, in Boston, Massachusetts. Bill Welch, Chief Executive Officer of Trovagene, will be attending the conference which consists of one-on-one investor meetings as well as small group meetings. No formal presentations are being made.
TROV: 4.87 (-0.04)
Trovera(TM) Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer
PR Newswire - Tue Aug 09, 7:30AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that a patient case report featuring use of the Company's Trovera(TM) EGFR urine-based liquid biopsy test was recently published in Experimental Hematology & Oncology. Dr. David Berz, medical oncologist at the Beverly Hills Cancer Center in Beverly Hills, CA, authored the manuscript titled, Non-invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer: A Case Report
TROV: 4.87 (-0.04)
TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:33AM CDT
TrovaGene Inc (TROV) reported loss of 34 cents per share in the second quarter of 2016, narrower than the year-ago loss of 41 cents.
BABY: 39.02 (+0.11), MASI: 58.81 (-0.33), TROV: 4.87 (-0.04), MLAB: 110.52 (-1.84)
Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments
PR Newswire - Thu Aug 04, 3:15PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today reported its financial results and accomplishments for the second quarter ended June 30, 2016.
TROV: 4.87 (-0.04)
Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 50.63 (-0.47), TROV: 4.87 (-0.04), ANIP: 61.66 (+1.92), GLYC: 7.47 (+0.06)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 3:37AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations.
IRMD: 18.21 (-0.46), MASI: 58.81 (-0.33), TROV: 4.87 (-0.04), EXAC: 27.68 (-0.11)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:39AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
IRMD: 18.21 (-0.46), MASI: 58.81 (-0.33), TROV: 4.87 (-0.04), EXAC: 27.68 (-0.11)
ASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer
PR Newswire - Mon Jun 06, 10:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced the presentation of clinical results demonstrating highly sensitive detection of EGFR T790M mutations in the urine of patients with non-small cell lung cancer. The oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, entitled Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients treated with rociletinib, was delivered today by Heather Wakelee, M.D. of Stanford University http://abstracts.asco.org/176/AbstView_176_167439.html.
TROV: 4.87 (-0.04)
Why These Stocks are Under the Investor Community's Microscope? - Bruker, Quintiles Transnational Holdings, iKang Healthcare Group, and TrovaGene
PR Newswire - Wed Jun 01, 7:20AM CDT
In today's pre-market research, ActiveWallSt.com has selected the following Medical Laboratories and Research stocks for your evaluation: Bruker Corp. (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), iKang Healthcare Group Inc. (NASDAQ: KANG), and TrovaGene Inc. (NASDAQ: TROV). Access these equities free technical alerts at:
Q: 77.24 (-0.06), TROV: 4.87 (-0.04), KANG: 18.28 (-0.16), BRKR: 22.39 (+0.03)
Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting
PR Newswire - Thu May 19, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that diagnostic performance results using the Company's Precision Cancer Monitoring® platform to detect and monitor EGFR T790M in the urine of non-small cell lung cancer (NSCLC) patients will be the subject of an oral presentation given by Heather Wakelee, M.D., Stanford University Medical Center, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts for the ASCO meeting were released last night, and can be viewed at http://abstracts.asco.org/
TROV: 4.87 (-0.04)
TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:16AM CDT
TrovaGene Inc (TROV) reported adjusted loss of 36 cents per share in the first quarter of 2016, wider than the year-ago loss of 33 cents.
TROV: 4.87 (-0.04), TECH: 106.55 (+1.20), EXAC: 27.68 (-0.11), NVRO: 94.80 (+0.37)
Trovagene reports 1Q loss
Automated Insights - Tue May 10, 4:25PM CDT
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Tuesday reported a loss of $10.3 million in its first quarter.
TROV: 4.87 (-0.04)
Trovagene Announces First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016.
TROV: 4.87 (-0.04)
Lifshitz & Miller Law Firm Announces Investigation of Apigee Corporation, Mentor Graphics Corp., PayPal Holdings Inc., Performance Sports Group, Ltd., PJT Partners, Inc., and Trovagene, Inc.
PR Newswire - Thu May 05, 12:13PM CDT
Apigee Corporation (APIC)
PSG: 2.72 (+0.01), APIC: 15.35 (+0.04), MENT: 24.06 (+0.05), TROV: 4.87 (-0.04), PJT: 24.58 (-0.09), PYPL: 36.78 (-0.37)
Trovagene Schedules Release of First Quarter 2016 Financial Results and Investor Conference Call
PR Newswire - Tue May 03, 7:15AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 on Tuesday, May 10, 2016 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
TROV: 4.87 (-0.04)
Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference
PR Newswire - Thu Apr 28, 7:15AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that its Chief Scientific Officer, Mark Erlander, Ph.D. will present a corporate overview at the 41st Annual Deutsche Bank Healthcare Conference taking place May 4-5, 2016 at the InterContinental Hotel in Boston, MA.
TROV: 4.87 (-0.04), DB: 14.66 (-0.09)
What's in Store for TrovaGene (TROV) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:16AM CDT
TrovaGene Inc. (TROV) is expected to release first-quarter 2016 results on May 3.
BDX: 176.09 (-1.12), PRXL: 67.79 (-0.24), ALGN: 92.69 (-0.21), TROV: 4.87 (-0.04)
Trovagene Appoints Bill Welch as Chief Executive Officer
PR Newswire - Mon Apr 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the appointment of William (Bill) Welch as Chief Executive Officer, effective immediately. In addition, the Company announced that Matthew Posard, the Company's Chief Commercial Officer, has left the Company.
TROV: 4.87 (-0.04)
TrovaGene Inks Strategic Partnership with Stratose, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 12:10PM CDT
Shares of TrovaGene Inc. (TROV) climbed 1.8% (9 cents) to close at $5.10 on Apr 11, following the announcement of a new strategic agreement with Stratose Inc.
TROV: 4.87 (-0.04), GILD: 77.57 (-0.81), AMAG: 23.64 (-0.19), ANIK: 46.84 (-0.40)
Blue Cross Blue Shield Illinois to Cover Trovera(TM) Liquid Biopsy Tests
PR Newswire - Wed Aug 17, 7:30AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois (BCBSIL) establishing health benefit access to the full line of Trovagene's tests and services.
TROV: 4.87 (-0.04)
Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference
PR Newswire - Tue Aug 09, 9:34AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 2016 Avondale Partners Healthcare 1-1 Conference on Wednesday, August 10, 2016 at the Boston Harbor Hotel, in Boston, Massachusetts. Bill Welch, Chief Executive Officer of Trovagene, will be attending the conference which consists of one-on-one investor meetings as well as small group meetings. No formal presentations are being made.
TROV: 4.87 (-0.04)
Trovera(TM) Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer
PR Newswire - Tue Aug 09, 7:30AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that a patient case report featuring use of the Company's Trovera(TM) EGFR urine-based liquid biopsy test was recently published in Experimental Hematology & Oncology. Dr. David Berz, medical oncologist at the Beverly Hills Cancer Center in Beverly Hills, CA, authored the manuscript titled, Non-invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer: A Case Report
TROV: 4.87 (-0.04)
TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:33AM CDT
TrovaGene Inc (TROV) reported loss of 34 cents per share in the second quarter of 2016, narrower than the year-ago loss of 41 cents.
BABY: 39.02 (+0.11), MASI: 58.81 (-0.33), TROV: 4.87 (-0.04), MLAB: 110.52 (-1.84)
Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments
PR Newswire - Thu Aug 04, 3:15PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today reported its financial results and accomplishments for the second quarter ended June 30, 2016.
TROV: 4.87 (-0.04)
Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 50.63 (-0.47), TROV: 4.87 (-0.04), ANIP: 61.66 (+1.92), GLYC: 7.47 (+0.06)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 3:37AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations.
IRMD: 18.21 (-0.46), MASI: 58.81 (-0.33), TROV: 4.87 (-0.04), EXAC: 27.68 (-0.11)
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:39AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
IRMD: 18.21 (-0.46), MASI: 58.81 (-0.33), TROV: 4.87 (-0.04), EXAC: 27.68 (-0.11)
ASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer
PR Newswire - Mon Jun 06, 10:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced the presentation of clinical results demonstrating highly sensitive detection of EGFR T790M mutations in the urine of patients with non-small cell lung cancer. The oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, entitled Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients treated with rociletinib, was delivered today by Heather Wakelee, M.D. of Stanford University http://abstracts.asco.org/176/AbstView_176_167439.html.
TROV: 4.87 (-0.04)
Why These Stocks are Under the Investor Community's Microscope? - Bruker, Quintiles Transnational Holdings, iKang Healthcare Group, and TrovaGene
PR Newswire - Wed Jun 01, 7:20AM CDT
In today's pre-market research, ActiveWallSt.com has selected the following Medical Laboratories and Research stocks for your evaluation: Bruker Corp. (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), iKang Healthcare Group Inc. (NASDAQ: KANG), and TrovaGene Inc. (NASDAQ: TROV). Access these equities free technical alerts at:
Q: 77.24 (-0.06), TROV: 4.87 (-0.04), KANG: 18.28 (-0.16), BRKR: 22.39 (+0.03)
Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting
PR Newswire - Thu May 19, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that diagnostic performance results using the Company's Precision Cancer Monitoring® platform to detect and monitor EGFR T790M in the urine of non-small cell lung cancer (NSCLC) patients will be the subject of an oral presentation given by Heather Wakelee, M.D., Stanford University Medical Center, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts for the ASCO meeting were released last night, and can be viewed at http://abstracts.asco.org/
TROV: 4.87 (-0.04)
TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:16AM CDT
TrovaGene Inc (TROV) reported adjusted loss of 36 cents per share in the first quarter of 2016, wider than the year-ago loss of 33 cents.
TROV: 4.87 (-0.04), TECH: 106.55 (+1.20), EXAC: 27.68 (-0.11), NVRO: 94.80 (+0.37)
Trovagene reports 1Q loss
Automated Insights - Tue May 10, 4:25PM CDT
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Tuesday reported a loss of $10.3 million in its first quarter.
TROV: 4.87 (-0.04)
Trovagene Announces First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016.
TROV: 4.87 (-0.04)
Lifshitz & Miller Law Firm Announces Investigation of Apigee Corporation, Mentor Graphics Corp., PayPal Holdings Inc., Performance Sports Group, Ltd., PJT Partners, Inc., and Trovagene, Inc.
PR Newswire - Thu May 05, 12:13PM CDT
Apigee Corporation (APIC)
PSG: 2.72 (+0.01), APIC: 15.35 (+0.04), MENT: 24.06 (+0.05), TROV: 4.87 (-0.04), PJT: 24.58 (-0.09), PYPL: 36.78 (-0.37)
Trovagene Schedules Release of First Quarter 2016 Financial Results and Investor Conference Call
PR Newswire - Tue May 03, 7:15AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 on Tuesday, May 10, 2016 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
TROV: 4.87 (-0.04)
Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference
PR Newswire - Thu Apr 28, 7:15AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that its Chief Scientific Officer, Mark Erlander, Ph.D. will present a corporate overview at the 41st Annual Deutsche Bank Healthcare Conference taking place May 4-5, 2016 at the InterContinental Hotel in Boston, MA.
TROV: 4.87 (-0.04), DB: 14.66 (-0.09)
What's in Store for TrovaGene (TROV) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:16AM CDT
TrovaGene Inc. (TROV) is expected to release first-quarter 2016 results on May 3.
BDX: 176.09 (-1.12), PRXL: 67.79 (-0.24), ALGN: 92.69 (-0.21), TROV: 4.87 (-0.04)
Trovagene Appoints Bill Welch as Chief Executive Officer
PR Newswire - Mon Apr 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the appointment of William (Bill) Welch as Chief Executive Officer, effective immediately. In addition, the Company announced that Matthew Posard, the Company's Chief Commercial Officer, has left the Company.
TROV: 4.87 (-0.04)
TrovaGene Inks Strategic Partnership with Stratose, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 12:10PM CDT
Shares of TrovaGene Inc. (TROV) climbed 1.8% (9 cents) to close at $5.10 on Apr 11, following the announcement of a new strategic agreement with Stratose Inc.
TROV: 4.87 (-0.04), GILD: 77.57 (-0.81), AMAG: 23.64 (-0.19), ANIK: 46.84 (-0.40)
